Moreover, CXCL1 signalling in the tumour microenvironment is associated with tumour progression, tumour recurrence and drug resistance; [65] therefore, targeting CXCL1 signalling is a potential therapeutic approach for human BC. Here, CXCL1 is linked to neoplasm.